Core Viewpoint - The company expects a significant decrease in net profit attributable to shareholders for the fiscal year ending December 31, 2025, compared to the previous year, primarily due to rising labor and material costs, as well as strategic adjustments to maintain market share [1] Financial Performance - The anticipated net profit attributable to shareholders for the fiscal year is projected to be between HKD 57 million and HKD 68 million [1] - This represents a decrease of approximately 37.0% to 47.0% compared to the net profit of approximately HKD 108 million for the fiscal year ending December 31, 2024 [1] Cost Factors - The decline in net profit is attributed to two main factors: 1. Increased direct labor costs and raw material costs [1] 2. Strategic initiatives to optimize the product line and offer more competitively priced products in response to customer price sensitivity, which have led to a decrease in gross profit and gross profit margin [1]

Group 1 - The stock price of Tianxin Pharmaceutical (603235) has shown volatility in the past week, closing at 27.21 yuan on February 12, 2026, with a decrease of 0.98% on that day and a trading volume of 15.16 million yuan, indicating short-term pressure on capital flow [1] - Over the past five days, the cumulative increase in stock price is 1.08%, but on February 12, there was a net outflow of 518,900 yuan from main funds, suggesting a challenging short-term funding environment [1] - The stock is currently near a 20-day resistance level of 27.57 yuan, with the Bollinger Band's middle track at 27.11 yuan, and the KDJ indicator's J line at 82.58, indicating a high position that requires attention to momentum changes after breaking the resistance level [1] Group 2 - The company's Q3 2025 financial report shows a revenue of 1.631 billion yuan for the first three quarters, representing a year-on-year growth of 1.08%, while the net profit attributable to shareholders is 460 million yuan, reflecting a year-on-year decrease of 6.91% [2] - In Q3 alone, revenue was 509 million yuan, down 7.02% year-on-year, with the net profit decline expanding to 30.15%, primarily due to fluctuations in vitamin industry demand and cost pressures [2] - The gross profit margin remains at 45.34%, but the net profit margin has narrowed [2] Group 3 - Institutional attention towards Tianxin Pharmaceutical has been low recently, with only one institution giving a "buy" rating in the last 90 days [3] - Institutions focus on the company's global market share advantages in Vitamin B6 and B1, which are leading positions, and the overseas revenue proportion of 51.52% that benefits from the depreciation of the yuan [3] - However, there is a need to be cautious about intensified industry competition that may challenge the sustainability of profitability [3]

Core Viewpoint - Deutsche Bank (02418) anticipates a significant decline in net profit for the fiscal year ending December 31, 2025, projecting a range of approximately RMB 45 million to RMB 55 million, which represents a decrease of about 65% to 71% compared to the net profit of RMB 157 million for the fiscal year ending December 31, 2024 [1] Group 1: Financial Projections - The expected net profit for 2025 is projected to be between RMB 45 million and RMB 55 million [1] - This represents a substantial decrease of approximately 65% to 71% from the previous year's net profit of RMB 157 million [1] Group 2: Reasons for Profit Decline - Increased competition in the domestic financing leasing and supply chain logistics industries is a primary factor contributing to the anticipated decline in net profit [1] - To enhance competitiveness in response to market conditions, the company is increasing its investment in business policy costs, leading to higher operational costs and a reduction in overall gross profit margin compared to the previous year [1] - The company has also raised the general provision for impairment of accounts receivable and specific credit impairment provisions for individual clients due to changes in overall market risk, which negatively impacts overall profit performance [1]

Core Viewpoint - The company Hongbaoli (002165) expects a significant decline in net profit for the fiscal year 2025, projecting a range of 16 million to 24 million yuan, which represents a year-on-year decrease of 58.97% to 72.65% [1] Group 1: Financial Performance - The anticipated net profit for 2025 is between 16 million and 24 million yuan, indicating a substantial decline compared to the previous year [1] - The decrease in profit is attributed to several factors, including a drop in the gross profit margin due to lower raw material procurement prices and a corresponding reduction in product prices [1] Group 2: Market and Product Development - The company is actively expanding its domestic and international markets for polyether and isopropanolamine products, with total product sales continuing to grow [1] Group 3: Operational Challenges - The appreciation of the RMB against the USD and the ongoing project construction phase at the subsidiary Taixing Chemical, along with asset impairment from the dismantling of equipment, have negatively impacted operating profits compared to the previous year [1]

Core Viewpoint - Hongchang Technology (301008.SZ) expects a significant decline in net profit for 2025, projecting a decrease of 50% to 60% compared to the previous year [1] Financial Performance - The estimated net profit attributable to shareholders for 2025 is between 20.9863 million and 26.2329 million yuan [1] - The net profit after deducting non-recurring gains and losses is projected to be between 9.7425 million and 13.6395 million yuan, reflecting a decline of 65% to 75% year-on-year [1] Contributing Factors - The decline in profit is attributed to several factors, including the accrual of convertible bond interest, share-based payments related to the employee stock ownership plan, and rising raw material prices [1]

Core Viewpoint - China Shenhua (601088) expects a decline in net profit attributable to shareholders for the fiscal year 2025, projecting between RMB 50.8 billion and RMB 55.8 billion, which represents a decrease of 10.6% to 18.6% compared to the previously disclosed figure for 2024 of RMB 62.421 billion [1] Financial Performance - The projected profit for 2025 shows a decline of 14.7% to 6.3% when compared to the restated figure for 2024 of RMB 59.544 billion [1] - The company's operational performance remains stable, with core advantages in integrated operations continuing to strengthen [1] Market Conditions - The decline in operating performance is attributed to changes in industry supply and demand dynamics, leading to a decrease in coal sales volume and average selling prices [1] - Energy security and stable supply are effectively ensured despite the challenges faced [1]

Core Viewpoint - Wanhe Electric (002543.SZ) expects a significant decline in net profit for 2025, projecting a range of 140 million to 205 million yuan, which represents a decrease of 68.83% to 78.71% compared to the previous year [1] Financial Performance - The net profit attributable to shareholders is forecasted to be between 140 million and 205 million yuan, indicating a substantial year-on-year decline [1] - The net profit after deducting non-recurring gains and losses is estimated to be between 210 million and 310 million yuan, reflecting a decrease of 52.77% to 68.01% year-on-year [1] Impact Factors - The preliminary valuation results from Qianhai Equity Investment Fund indicate a decrease in fair value change income by approximately 30.49 million yuan year-on-year [1] - A reduction in government subsidies is expected to lead to a decrease in other income by about 26.26 million yuan year-on-year [1] - Both of these impacts are included in non-recurring gains and losses [1]

Core Viewpoint - The company expects a significant decline in net profit for the fiscal year 2025, projecting a range of 20 million to 25 million yuan, which represents a year-on-year decrease of 59.79% to 67.83% [1] Financial Performance - The primary reason for the anticipated decline in net profit for 2025 is the absence of non-recurring gains that were present in 2024, specifically the transfer of a 12.2807% stake in Zhejiang Yindun Cloud Technology Co., Ltd. for 428 million yuan, which contributed an increase of 30.1491 million yuan to the 2024 net profit [1] - In addition to the lack of investment gains from equity transfers and property disposals in 2025, the company is also facing a reduction in interest income due to lower bank deposit rates and changes in the allocation of funds towards construction projects and external investments [1]

Core Viewpoint - The company expects a net profit of 20.6 million yuan for the fiscal year 2025, representing a significant year-on-year decline of 70.66% [1] Financial Performance - The substantial change in the company's performance compared to the same period last year is primarily due to several factors [1] - In the previous year, the company recognized a value-added tax credit of approximately 26 million yuan, while this year the benefit is recorded as 0 yuan [1] - During the reporting period, the company increased its credit impairment losses by approximately 16 million yuan compared to the same period last year, reflecting a cautious approach [1] Market Conditions - The company experienced a decline in product gross margin year-on-year due to intensified market competition and other external environmental factors [1] Subsidiary Impact - The bankruptcy liquidation of the company's controlling subsidiary, Beijing Yuanlu Cultural Development Co., Ltd., resulted in a reduction of approximately 18 million yuan in net profit attributable to the shareholders of the listed company [1]

Core Viewpoint - The company expects a significant decline in net profit for the year 2025, projecting a range of 8.5 to 11.5 million yuan, which represents a year-on-year decrease of 69.23% to 77.25% [1] Group 1 - The main raw materials, copper and silver, have seen continuous price increases, which have adversely affected the company's gross profit margin due to a lag in product price adjustments [1] - The company plans to make impairment provisions for related assets based on a principle of prudence, which will negatively impact the overall net profit for the reporting period [1]